Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.57 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.57 |
| ▸ | CTSB | P07858 | 4/20 | 0.56 |
| ▸ | CTSK | P43235 | 4/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.56 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.56 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21772506 | 1.00 | CTSL (0.57) | CTSLCAPN1CTSBCTSKCTSS | |
| SCHEMBL29530534 | 0.96 | CTSL (0.56) | CTSLCAPN1CTSBCTSKCTSS | |
| SCHEMBL19605947 | 0.96 | CTSL (0.56) | CTSLCAPN1CTSBCTSKCTSS | |
| SCHEMBL19606040 | 0.96 | CTSL (0.56) | CTSLCAPN1CTSBCTSKCTSS | |
| SCHEMBL29530339 | 0.96 | CTSL (0.56) | CTSLCAPN1CTSBCTSKCTSS | |
| SCHEMBL22875604 | 0.95 | CTSL (0.63) | CTSLCAPN1CTSBCTSKCTSS | |
| SCHEMBL21772510 | 0.93 | CTSL (0.51) | CTSLCAPN1CTSB | |
| SCHEMBL21772509 | 0.93 | CTSL (0.51) | CTSLCAPN1CTSB | |
| SCHEMBL21786582 | 0.93 | CTSL (0.53) | CTSLCAPN1CTSBCTSKCTSS | |
| SCHEMBL29530148 | 0.93 | CTSL (0.53) | CTSLCAPN1CTSBCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071354-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | EMORY UNIVERSITY (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071354-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | VIP, HAVCR2, NGLY1 | CTSL 280/4885CAPN1 404/4885CTSB 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.